Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase

PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec 12, 2024--

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21, 2025.

“Zoetis’ performance has been strong this year, driven by our diverse, science-driven portfolio and our differentiated execution,” said Wetteny Joseph, Executive Vice President and Chief Financial Officer at Zoetis. “I am pleased to announce that we are increasing our dividend in 2025, consistent with our commitment to returning excess capital to shareholders.”

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online atwww.sec.gov,www.zoetis.com, or on request from Zoetis.

ZTS-COR
ZTS-IR
ZTS-FIN

View source version on businesswire.com:https://www.businesswire.com/news/home/20241212274866/en/

CONTACT: Media Contacts:

Jennifer Albano

1-973-945-4333 (o)

jennifer.albano@zoetis.com

Laura Panza

1-973-975-5176 (o)

laura.panza@zoetis.com

Investor Contacts:

Steve Frank

1-973-822-7141 (o)

steve.frank@zoetis.com

Nick Soonthornchai

1-973-443-2792 (o)

nick.soonthornchai@zoetis.com

KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH MANAGED CARE PHARMACEUTICAL BIOTECHNOLOGY VETERINARY

SOURCE: Zoetis Inc.

Copyright Business Wire 2024.